The document discusses Furocyst, an innovative fenugreek seed extract developed for PCOS management. It has received two US patents and is manufactured in an GMP-certified facility. Two clinical studies on 107 and 50 subjects found that Furocyst significantly reduced ovary volume and cyst size, increased pregnancy and regular menstrual cycles, and was proven safe. The extract has been presented internationally and selected for a Prime Minister fellowship to study its mechanism of action.

1. Furocyst- An Innovation in Pcos
Management,
its
Publications & Presentations….
An Insight

2. A Novel Trigonella foenum-graecum
seed extract enriched in furostanolic
saponins was developed and
manufactured in our GMP-NSF
certified manufacturing plant.
US Patent 8217165B2 July 10, 2012
US Patent 8754205B2 June 17, 2014
Each capule contains
Fenugreek Seeds Extract 500 mg

3. Salient Features of
U.S. patented research-based,
innovative ingredient
Patent protected process
Stable with a 3-years shelf life
Two capsule dosage formula in
veggie capsules
Water soluble ingredient
Manufactured in WHO-GMP,
9001:2015, ISO 22000:2005,
KOSHER, HALAL, ZED-Gold,
NSF-US GMP certified
manufacturing facility

4. Important News on
Furocyst (For PCOS Management) has
been selected under Prime Minister’s
Fellowship for Doctoral
Research’ scheme.
New clinical study on 375 subjects
has been initiated by PGIMER (Post
Graduate Institute of Medical
Education & Research), one of the most
prestigious Government hospital in
India.

5. Clinical Evaluation of
Study 1 carried on 107 PCOS subjects
Efficacy conclusions
• The left ovary volume was decreased in 90% of
the patients and right ovary volume was
decreased in 96.7%.
• The mean cyst size in the right ovary was reduced
up to 41.57% & in left ovaries, it was decreased
significantly up to 44.92%.
• Fifteen patients got pregnant during the study
• HOMA index also reduced significantly in 75.67%
patients.
• 79.5% of the study population had regular
menstrual cycle.
• Mean Prolactin levels were decreased
significantly.

6. Clinical Evaluation of
Study 2 carried on 50 PCOS subjects
Efficacy conclusions
• Fenugreek seed extract caused significant
reduction in the ovary volume.
• 46% of the study population showed reduction in
the cyst size.
• 36% of the study population showed complete
dissolution of the cysts.
• 12% of the patients got pregnant.
• 71% of the patients reported regular menstrual
cycle on completion of the treatment.
• Overall 94% of the patients reported positively or
got benefitted from the fenugreek extract dosing.

7. Clinical Evaluation of
Safety conclusions
• No significant change in liver function tests
was observed.
• No significant change in renal function tests
was observed.
• No significant change in hemoglobin levels
and differential leukocyte count (DLC).
• Investigational product was proven safe for
consumption.

8. Publications
in
International Journals

13. Presentations
in
International conferences

16. Poster Presentation

20. PRIME MINISTER
FELLOWSHIP SCHEME FOR
DOCTORAL RESEARCH
ON MECHANISM OF ACTION
OF FUROCYST
AT KING GEORGE’S MEDICAL
UNIVERSITY, LUCKNOW

24. How do we make

25. www.furocyst.com